Neuroprotective effect of 3-oxo-3-p-tolyl-propyl- chromane-4-one in conditions of experimental ischemia-reperfusion of the brain

The treatment of acute cerebral circulatory disorders and, in particular, ischemic stroke is a complex interdisciplinary task. One of the directions of therapy for ischemic stroke may be the use of neuroprotectors, pharmacologically active compounds that prevent the alteration of cerebral cells during the manifestation of the process of ischemic brain damage. The aim of the study was to experimentally analyze the neuroprotective potential of 3-oxo-3-p-tolyl-propyl-chromene-4-one in laboratory animals with ischemic reperfusion injury of the brain. Cerebral ischemia-reperfusion was modeled on Wistar rats by the method of filamentous occlusion of the middle cerebral artery. The range of analyzed doses for the tested object was selected as follows: 15 mg/kg, 30 mg/kg, 45 mg/kg and 60 mg/kg. The reference was ethylmethylhydroxypyridine succinate at a dose of 50 mg/kg. This study demonstrated that when the studied object, 3–oxo-3-p-tolyl-propyl-chromene-4-one, was administered to animals at doses of 30 mg/kg, 45 mg/kg and 60 mg/kg, an increase in the activity of the mitochondrial enzymes succinate dehydrogenase and cytochrome c oxidase was observed, while the indicators the groups that are receiving the test substance did not differ from those of the rats treated by the reference. Also, against the background of the administration of the studied compound and the reference agent, a decrease in the concentration of apoptosis-inducing factor and mitochondrial hydrogen peroxide was noted, in comparison with the indicators of the group of untreated rats. The obtained data indicate the presence of 3-oxo-3-p-tolyl-propyl-chromene-4-one neuroprotective activity comparable to that of ethylmethylhydroxypyridine succinate, which makes this compound promising for further study as a neuroprotector used in conditions of ischemic stroke.